Results
cancer, anogenital cancers, cervical cancer, anal cancer
ADVERSE EVENTS, CANCER, BEST, CERVICAL CANCER, ANAL CANCER, PENILE CANCER
Between November 2018 and October 2020, there were 21 patients with advanced HPV-associated anogenital cancers treated with durvalumab and MEDI0457: cervical cancer (Characteristics of study participants evaluable for response (There were 19 patients evaluable for the primary endpoint—10 in the cervical cancer cohort and 9 in the ­non-cervical cancer cohort. Two patients were not evaluable for response due to rapid clinical deterioration. There was 1 participant with cervical cancer who experienced a complete radiographic response, and 3 participants (2 with anal cancer and 1 with penile cancer) with partial responses. For the entire study population (Best radiographic response.Waterfall plot.As seen in Progression-free survival (Median OS (Overall, durvalumab and MEDI0457 demonstrated acceptable safety and tolerability (Treatment-related adverse events.